USA flag logo/image

An Official Website of the United States Government

IGF::OT::IGF OTHER FUNCTIONS PHASE I, TOPIC 309, LABEL-FREE MULTIVARIATE…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
N43CO120071
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
AMBERGEN, INC
AMBERGEN, INC 313 PLEASANT ST WATERTOWN, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: IGF::OT::IGF OTHER FUNCTIONS PHASE I, TOPIC 309, LABEL-FREE MULTIVARIATE CANCER DIAGNOSIS
Agency: HHS
Contract: N43CO120071
Award Amount: $199,767.00
 

Abstract:

Significant progress has been made recently in developing multi-analyte prognostic cancer signatures based on gene expression profiling (GEP). However, current industry-standard RT-PCR platforms require substantial amounts of clinical samples, such as multiple FFPE tumor sections. These large sample requirements preclude less invasive biopsy sampling techniques, such as fine needle aspiration. In addition, few patients and/or signatures can be assayed simultaneously on standard RT-PCR platforms due to limited spatial and analytical capacity, thereby driving up assay cost. To meet these challenges, a new RT-PCR platform for measuring multi-analyte prognostic cancer signatures will be evaluated. Based on WaferGen s SmartChip technology, this platform willenable template requirements to be reduced by 1/16th of conventional amounts while dramatically increasing the number of patients and signatures that may be run simultaneously. This innovation will greatly reduce costs and make such prognostic assays moreaccessible to cancer patients. In phase I, the new approach will be evaluated utilizing AmberGen s 12-gene colorectal cancer prognostic signature, which achieved 95% sensitivity and 99% specificity to predict recurrence in a blinded study. A custom SmartChip will be designed to enable the CRC recurrence signature to be measured simultaneously for 48 patients, and is expected to achieve similar levels of accuracy.

Principal Investigator:

Christopher Sears
617-923-9990
CSEARS@AMBERGEN.COM

Business Contact:

Christopher Sears
617-923-9990
CSEARS@AMBERGEN.COM
Small Business Information at Submission:

AMBERGEN, INC
AMBERGEN, INC 313 PLEASANT ST WATERTOWN, MA -

EIN/Tax ID: 104322800
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No